公开(公告)号：US10561713B2

公开(公告)日：2020-02-18

申请号：US15738017

申请日：2016-07-04

Applicant: GREEN CROSS CORPORATION ,  MEDIGENEBIO CORPORATION

Inventor： Jin-Kyung Lee ,  Han-Yeul Byun ,  Myung-Eun Jung ,  Kyu-Hyun Lee

IPC: A61K38/46 ,  A61K9/00 ,  A61K38/16 ,  A61P3/00 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26

Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.